Amanda Freeman

1.1k total citations
13 papers, 748 citations indexed

About

Amanda Freeman is a scholar working on Oncology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Amanda Freeman has authored 13 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Infectious Diseases and 3 papers in Pharmacology. Recurrent topics in Amanda Freeman's work include Bone health and treatments (3 papers), Asthma and respiratory diseases (3 papers) and Epilepsy research and treatment (2 papers). Amanda Freeman is often cited by papers focused on Bone health and treatments (3 papers), Asthma and respiratory diseases (3 papers) and Epilepsy research and treatment (2 papers). Amanda Freeman collaborates with scholars based in United States, Belgium and United Kingdom. Amanda Freeman's co-authors include Sherry D. Holland, Kenneth C. Lasseter, Barry J. Gertz, Yosuke Okada, Scott G. Morham, Lawrence G. Raisz, Arturo G. Porras, Carol C. Pilbeam, Joseph A. Lorenzo and Masato Tomita and has published in prestigious journals such as Journal of Clinical Investigation, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Amanda Freeman

13 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amanda Freeman United States 11 287 188 177 148 113 13 748
Mark Allison United States 9 137 0.5× 65 0.3× 171 1.0× 104 0.7× 42 0.4× 14 514
Sarah Shugarts United States 9 259 0.9× 63 0.3× 130 0.7× 30 0.2× 22 0.2× 13 691
Jon Ruckle United States 12 118 0.4× 66 0.4× 248 1.4× 62 0.4× 50 0.4× 22 672
Mirjana Cvetković Serbia 10 903 3.1× 147 0.8× 215 1.2× 135 0.9× 37 0.3× 21 1.4k
Landry K. Kamdem United States 12 338 1.2× 59 0.3× 162 0.9× 67 0.5× 12 0.1× 21 898
Kaoru Ueda Japan 11 338 1.2× 62 0.3× 91 0.5× 15 0.1× 69 0.6× 33 760
Sameh R. Abul‐Ezz United States 14 179 0.6× 52 0.3× 133 0.8× 12 0.1× 19 0.2× 26 800
Chang-Hong Jiang China 9 108 0.4× 62 0.3× 122 0.7× 18 0.1× 30 0.3× 14 478
Marija Popović Canada 12 65 0.2× 64 0.3× 83 0.5× 11 0.1× 34 0.3× 45 601
Taiji Sawamoto Japan 17 159 0.6× 60 0.3× 100 0.6× 8 0.1× 18 0.2× 30 644

Countries citing papers authored by Amanda Freeman

Since Specialization
Citations

This map shows the geographic impact of Amanda Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Freeman more than expected).

Fields of papers citing papers by Amanda Freeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Freeman. The network helps show where Amanda Freeman may publish in the future.

Co-authorship network of co-authors of Amanda Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Freeman. A scholar is included among the top collaborators of Amanda Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Freeman. Amanda Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Appleton, Richard, Amanda Freeman, & J. Helen Cross. (2012). Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Archives of Disease in Childhood. 97(12). 1073–1076. 28 indexed citations
2.
Nakhla, Meranda, Andrew Denker, James D. Connor, et al.. (2011). Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children. Clinical Therapeutics. 33(10). 1516–1523. 10 indexed citations
3.
Stone, Julie A., Elizabeth Migoya, Lisa Hickey, et al.. (2004). Potential for Interactions between Caspofungin and Nelfinavir or Rifampin. Antimicrobial Agents and Chemotherapy. 48(11). 4306–4314. 74 indexed citations
4.
Stone, JA, Peter Wickersham, Paul Deutsch, et al.. (2001). Drug interactions between caspofungin and tacrolimus. 41. 1. 17 indexed citations
5.
Okada, Yosuke, Joseph A. Lorenzo, Amanda Freeman, et al.. (2000). Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. Journal of Clinical Investigation. 105(6). 823–832. 161 indexed citations
6.
Knorr, Barbara, Patrick Larson, Ha Nguyen, et al.. (1999). Montelukast Dose Selection in 6‐ to 14‐Year‐Olds: Comparison of Single‐Dose Pharmacokinetics in Children and Adults. The Journal of Clinical Pharmacology. 39(8). 786–793. 40 indexed citations
7.
Depré, Marleen, Anne Van Hecken, René Verbesselt, et al.. (1999). Effect of Multiple Doses of Montelukast, a CysLT1 Receptor Antagonist, on Digoxin Pharmacokinetics in Healthy Volunteers. The Journal of Clinical Pharmacology. 39(9). 941–944. 13 indexed citations
8.
Hecken, Anne Van, Marleen Depré, René Verbesselt, et al.. (1999). Effect of Montelukast on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers. The Journal of Clinical Pharmacology. 39(5). 495–500. 25 indexed citations
9.
Zhao, Jamie J., John Rogers, Sherry D. Holland, et al.. (1997). Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharmaceutics & Drug Disposition. 18(9). 769–777. 76 indexed citations
10.
Balani, Suresh K., Xin Xu, Vijaya S. Pratha, et al.. (1997). Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.. PubMed. 25(11). 1282–7. 75 indexed citations
11.
Gertz, Barry J., Sherry D. Holland, W. F. Kline, et al.. (1995). Studies of the oral bioavailability of alendronate*. Clinical Pharmacology & Therapeutics. 58(3). 288–298. 202 indexed citations
12.
Davey, Peter, Shannon Kelly, I. Jacobson, et al.. (1994). Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrobial Agents and Chemotherapy. 38(6). 1356–1362. 23 indexed citations
13.
Freeman, Amanda, et al.. (1978). CLINICAL DOSE‐RESPONSE STUDIES WITH GUANFACINE (BS 100‐141), A NEW ANTIHYPERTENSIVE AGENT. Clinical and Experimental Pharmacology and Physiology. 5(2). 187–190. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Allison Breakdown of academic impact, for papers by Sarah Shugarts Breakdown of academic impact, for papers by Jon Ruckle Breakdown of academic impact, for papers by Mirjana Cvetković Breakdown of academic impact, for papers by Landry K. Kamdem Breakdown of academic impact, for papers by Kaoru Ueda Breakdown of academic impact, for papers by Sameh R. Abul‐Ezz Breakdown of academic impact, for papers by Chang-Hong Jiang Breakdown of academic impact, for papers by Marija Popović Breakdown of academic impact, for papers by Taiji Sawamoto
Rankless by CCL
2026